Blankinship & Foster, LLC Abb Vie Inc. Transaction History

Blankinship & Foster, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Aug 14, 2024	SELL	$159.82 - $182.1 $22,854 - $26,040	-143 Reduced 0.91%	15,569 $2.84 Million
Q4 2023 Feb 09, 2024	BUY	$137.6 - $154.97 $19,814 - $22,315	144 Added 0.92%	15,712 $2.43 Million
Q3 2023 Oct 31, 2023	BUY	$133.59 - $154.65 $25,782 - $29,847	193 Added 1.26%	15,568 $2.32 Million
Q2 2023 Jul 24, 2023	BUY	$132.51 - $164.9 $46,776 - $58,209	353 Added 2.35%	15,375 $2.07 Million
Q1 2023 May 04, 2023	BUY	$144.61 - $166.54 $41,792 - $48,130	289 Added 1.96%	15,022 $2.39 Million
Q3 2022 Nov 08, 2022	SELL	$134.21 - $153.93 $13,421 - $15,393	-100 Reduced 0.67%	14,733 $1.98 Million
Q2 2022 Aug 10, 2022	BUY	$137.62 - $174.96 $103,215 - $131,220	750 Added 5.33%	14,833 $2.27 Million
Q1 2022 May 09, 2022	SELL	$131.98 - $163.75 $19,533 - $24,235	-148 Reduced 1.04%	14,083 $2.28 Million
Q4 2021 Feb 09, 2022	SELL	$107.43 - $135.93 $59,945 - $75,848	-558 Reduced 3.77%	14,231 $1.93 Million
Q3 2020 Nov 10, 2020	BUY	$85.91 - $100.83 $1.27 Million - $1.49 Million	14,789 New	14,789 $1.3 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $317B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Blankinship & Foster, LLC, based on Form 13F filings with the SEC.

Stay updated on Blankinship & Foster, LLC with notifications on news.